TABLE 1

HPLC/MS/MS conditions for the nine compounds


Compound

Retention Time

MRM Transition

Initial Gradient Conditions

Final Gradient Conditions

HPLC Columna
min
Carbamazepine (C) 2.3 237.09/194.20 A/B (90:10) A/B (10:90) BDS Hypersil C18 50 × 2.1 mm, 5 μm
Citalopram (Ci) 3.0 325.26/109.40 A/B (95:5) A/B (10:90) BDS Hypersil C18 50 × 2.1 mm, 5 μm
Ganciclovir (G) 2.2 256.18/152.10 A/B (95:5) A/B (10:90) Aquasil C18 50 × 4.6 mm, 5 μm
Metoclopramide (M) 2.0 301.21/228.10 A/B (90:10) A/B (10:90) BDS Hypersil C18 50 × 2.1 mm, 5 μm
N-Desmethylclozapine (N) 3.2 313.23/192.00 A/B (95:5) A/B (10:90) BDS Hypersil C18 50 × 2.1 mm, 5 μm
Quinidine (Q) 3.0 325.00/160.00 A/B (95:5) A/B (10:90) BDS Hypersil C18 50 × 2.1 mm, 5 μm
Risperidone (R) 2.5 411.20/191.30 A/B (90:10) A/B (10:90) BDS Hypersil C18 50 × 2.1 mm, 5 μm
9-OH-Risperidone (R9) 2.4 427.25/206.80 A/B (90:10) A/B (10:90) BDS Hypersil C18 50 × 2.1 mm, 5 μm
Thiopental (T)
3.8
241.04/101.00
A/B (90:10)
A/B (10:90)
BDS Hypersil C18 50 × 2.1 mm, 5 μm
  • MRM, multiple reaction monitoring.

    A, 0.1% formic acid.

    B, Acetonitrile/methanol/formic acid (49.95:49.95:0.1).

    C, Acetonitrile/formic acid (99.9:0.1).

  • a Thermo Fisher Scientific (Waltham, MA).